Intact parathyroid hormone (PTH) was analysed in 1107 samples over a 13 month period. Of these, 181 samples (1611/0) gave results of :e;; 1 pmol/L and the
case notes of 169 of these 181 patients were examined.
Eighty-two patients (4811/0) were hypercalcaemic at the time of the PTH assay. As expected, the most common diagnosis in this group was hypercalcaemia of malignancy but surprisingly this accounted for only 42 of the hypercalcaemic patients; an unexpectedly high proportion (20 patients) had chronic renal failure with hypercalcaemia due to excessive treatment with Io-hydroxycholecalciferol: eight patients had transient unexplained hypercalcaemia and the remaining 12 patients were hypercalcaemic for a variety of causes including immobilization, bendrofluazide treatment and Paget's disease.
Fifty-nine patients (35%) were normocalcaemic: 26 had osteoporosis, 10 had chronic renal failure and the remainder had a wide range of diagnoses. It is possible that the low intact PTH result in a proportion of the normocalcaemic group was caused by ingestion of calcium tablets prior to blood sampling for PTH.
Twenty-eight patients (17%) were hypocalcaemic: 24 of these had hypoparathyroidism, two had chronic renal failure and two had transient unexplained hypocalcaemia.
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The new immunometric assays for parathyroid hormone (PTH) allow the intact PTH peptide (1-84) to be measured in the low picomolar range. 1-3 This is sufficiently sensitive to measure the low amounts of hormone present in the serum of normal people so that the reference ranges now quoted include a lower limit of normal." The new assays are specific for intact hormone and do not suffer from interference from PTH fragments which tend to accumulate in patients with renal failure. S Therefore, the early diagnosis of secondary hyperparathyroidism in chronic renal failure is now possible and a large proportion of current requests for PTH analyses are on chronic renal failure patients.
Low or undetectable levels of PTH are expected in patients with non-hyperparathyroid hypercalcaemia and in patients with hypoparathyroidism.
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However, we noticed from the information given on our PTH request cards that low PTH results occurred in patients with high, low and normal serum calcium levels who had a wide range of clinical details so we decided to investigate the underlying diagnoses in patients with a low PTH result (:e;; 1 pmol/L).
METHODS
Over a 13 month period from April 1990 to May 1991, 1107 samples were analysed for PTH at the Royal Liverpool University Hospital (RLUH). Multiple requests for PTH on the same patient were taken into account so that each patient was counted only once. The majority of samples originated from RLUH patients, but samples were also received from several other hospitals in the North West of England. Samples accepted for analysis were received on ice and stored at PTH was measured in duplicate using the Incstar (Stillwater, Minnesota, USA) N-tact IRMA PTH kit." The reference range established in RLUH for the PTH assay was l' 1-6' 9 pmol/L and the minimum detection limit was O'6 pmol/L. Plasma or serum calcium was analysed using standard methodologies on a variety of automated analyser.
Calcium was adjusted for albumin as described 
Results
At the time of the PTH assay 82 patients (48%) were hypercalcaemic, 59 (35%) normocalcaemic and 28 (17%) hypocalcaemic. Table 1 lists the tumours causing hypercalcaemia of malignancy (HCM) and Table 2 the non-malignant causes of hypercalcaemia. Table 3 lists the diagnoses in patients with normocalcaemia and low PTH and Table 4 the diagnoses in patients with hypocalcaemia and low PTH. Figure 1 summarizes the findings in the entire group of patients with low PTH values.
DISCUSSION
The main applications of the intact PTH assay are in the differential diagnosis of hypercalcaemia and in the detection and management of bone disease and calcium disorders in chronic renal failure (CRF) patients.f It is also useful in diagnosing secondary hyperparathyroidism in patients who are normocalcaemic and in the differential diagnosis of hypocalcaemia. Not unexpectedly, the most common diagnosis we found among patients with low PTH results was HCM. What was surprising was that this group accounted for only 25070 of the total of patients with low PTH values and for only half of the patients with hypercalcaemia and low PTH values. Almost half of the HCM group had carcinoma of bronchus and most of the remainder had malignancies wellknown to cause HCM such as carcinoma of breast, renal cell carcinoma and myeloma. Some more unusual causes of HCM, e.g. anal squamous cell carcinoma, were also observed. Another cause of hypercalcaemia, which occurred in 20 CRF patients, was excessive treatment with la-hydroxycholecalciferol with or without calcium supplements. Some of these 20 patients were markedly hypercalcaemic: their mean serum calcium was 2· 95 mmollL (standard deviation O·25 mmollL) and the range of calcium results was 2· 69-3' 36 mmollL. Although no specific symptoms of hypercalcaemia had been noted, it may well have contributed to patients' non-specific symptoms. A large increase in the incidence of iatrogenic hypercalcaemia in chronic renal failure patients was also noted in a recent survey.? The degree of hypercalcaemia we observed in some CRF patients underlines the importance of frequent monitoring of serum calcium in these patients when they are on active vitamin D metabolites such as Io-hydroxycholecalciferol. Whether or not the aim of therapy in these patients should be to attain normal or low PTH levels which may result in beneficial effects on bone is a matter for future study.
Vitamin D supplements are widely prescribed to patients with osteoporosis and self medication with 'over-the-counter' preparations containing vitamin D is also common. This is reflected by the fact that three cases of hypercalcaemia due to vitamin D treatment (in non-renal failure patients) were observed.
To help establish the reference range for PTH, 60 normal controls were sampled and only one was found to have a PTH of~1 pmollL. However, 59 normocalcaemic patients had low PTH values (5070 of the total number of samples analysed). Ten of these patients had CRF and had a mean serum calcium of 2' 44 mmollL (standard deviation 0'16 mmollL); 26 had osteoporosis and had mean plasma calcium levels towards the upper end of the reference range at 2· 50 mmollL (standard deviation 0·08 mmollL). Five of the 10 CRF patients and 17 of the 26 osteoporotic patients were taking calcium supplements, and it is possible that they took their medications and thus suppressed their PTH levels prior to having their blood sampled. Ionized calcium has been shown to rise and intact PTH to fall (but remain detectable) following an acute oral calcium load in 38 healthy volunteers. 10 It may be that long-term ingestion of calcium and vitamin D in patients with osteoporosis may lead to a lower mean PTH level which is then suppressed following the ingestion of their morning calcium dose. Longitudinal study of calcium ingestion would be required to investigate this finding.
In the majority of the normocalcaemic group of patients, except in the group with CRF, it was unclear why the PTH estimation had been requested: for example, in the follow up of patients following removal of a parathyroid adenoma a PTH measurement is superfluous if the serum calcium is normal.
Thirteen of the 28 patients with low PTH concentrations were known to be hypoparathyroid: their PTH values were checked by our laboratory staff to assess the reliability of the assay in hypoparathyroidism. The high incidence of hypoparathyroidism following pharyngolaryngectomy reflects a local expertise in head and neck cancer surgery.
Patients found to have hypercalcaemia and low PTH values tend to be labelled probable hypercalcaemia of malignancy until proven otherwise.
However, our survey shows that this diagnosis will apply to only 500/0 of this group of patients. Overtreatment with Io-hydroxycholecalciferol, especially in CRF is another major cause, but rarer causes such as immobilization, Paget's disease, thiazide treatment and pulmonary tuberculosis should be excluded in patients with hypercalcaemia and low intact PTH concentrations.
Future research may define a further role for PTH assay in the follow up of patients on treatment with vitamin D or calcium. Longitudinal studies of patients on such treatment would be required to establish this role. In the meantime, the value of PTH measurement in normocalcaemic, non-renal failure patients is confined to the exclusion of suspected secondary hyperparathyroidism.
